newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis Submitted Type C meeting request to the FDA to meet during